Individualization of drug therapy requires that the right drug be administered at the correct dose to patients who are likely to achieve the highest benefit and lowest risk. Female sex and age comprise two important risk factors for altered drug exposure and response. This review summarizes the current state of science for considering age and sex-related factors along the drug development pipeline, from cell culture and animal research through all phases of clinical trials in humans. A set of recommendations is provided to improve standards for integrating age and sex into the study design, analysis, and reporting of pre-clinical and clinical assessment of new molecular entities and biologics in adults.
Introduction
A paradox in drug development is that medications are designed for the average patient, while precision medicine aims to tailor treatment based on age, sex, race and pharmacogenomics [1] . As long as women and older adults persist as special "subgroup" populations in both the European Medicines and United States Federal Drug Administration drug development guidance documents, this paradox will not be addressed [2, 3] . The irony of the "subgroup" designation can be contrasted against the biological and epidemiological relevance of age and sex among drug consumers. Although 51% of all human infants are born with an XY karyotype [4] , women outnumber men 5-3 by 80 years of age [5] . Sixty percent of prescription drug consumption occurs in adults over the age of 65 [6] , with women reporting significantly more side effects than men [7] . In Europe, the median age is already the highest in the world, and in 2050 there are projected to be 88.5 million Americans 65 years old or older [8] . Now, and more so in the future, the sex ratio of older drug consumers strongly favours women [9] . Integrating age and sex along the drug development pathway will minimize the likelihood of inter-individual variability in response to new molecular entities and the ever-increasing pharmacopeia of biologics.
This review offers a set of recommendations to improve the systematic consideration of sex and age across the spectrum of preclinical and clinical drug research. Enhancements to study design, data collection, biomarker selection, and standardized analytic approaches will increase the transparency and ultimate applicability of drug trial results according to an individual's age and sex. A better understanding of the mechanisms underlying observed differences in drug exposure and response will lead to the development of greater therapeutic risk-benefit profiling, and may spur the discovery of novel age-or sex-specific drug targets. For example, conducting research on the mechanisms of pain suppression in male and female animals revealed that chronic pain is mediated via different sex-specific regulatory pathways and distinct types of immune cells [10] . The treatment of pain is one of many pharmaceutical areas that lends itself to exploring the potential development of new sex-specific drug compounds.
How age and sex should be considered in drug development and testing
The core principle of stratification by age and sex in the development and testing of pharmacological compounds aims to unmask differences in drug exposure and response. Judicious selection of the study sample, disaggregation of the results by age and sex, and transparent reporting of any differences in the magnitude of effect are foundational elements that need to be included in all phases of investigation. Recommendations for considering age and sex may differ for each type of experimental design, as illustrated in Table 1 .
Distinct approaches to data collection and methodological analysis in vitro, animal and human studies are discussed.
In vitro experiments

Compare male and female cells
During the earliest stages of in vitro drug development research, the genetic sex of cultured cells and cells lines should be noted and reported [11] . If the genetic sex of transformed cell lines is unknown, genetic markers can be used to determine the genetic sex of the cells. At the simplest level, female cells have two X chromosomes, and male cells have one X and one Y chromosome. Occasionally, cells may exhibit altered ploidy or lack sex chromosomes [12] . All genetic permutations should be reported for purposes of rigour and reproducibility.
Gene size and organization of the X and Y-chromosomes are significantly different, and should be considered in relation to sexspecific pharmacogenetic and disease phenomenology [11, 13] . The human X chromosome is 155 Mb and contains 1669 known genes, almost 5% of the genes in the human genome. The Y chromosome is 59 Mb and contains 426 known genes. The role of the Y chromosome extends beyond housing the SRY gene that determines the development of the male gonadal phenotype and the initiation of male fertility. Mosaic loss of the Y chromosome in blood is associated with an increased risk of various diseases in men such as cancer and Alzheimer disease [14, 15] . Chromosome-specific genes encoding zinc finger (ZFX and ZFY) and ribosomal proteins (RPS4X and RPS4Y) are also located on the Y chromosome [11] .
Products of the X chromosome genes are involved in many aspects of cellular function, metabolism development, immune function and growth [16] . A multitude of traits are associated with loci on the X chromosome; mutations have been linked to sexspecific susceptibility to specific cancers, immune and metabolic diseases [13, 17] . Consideration of differential susceptibility can inform the development of new drug targets in fields such as oncology and immunology. Epigenetic regulation of sex-specific loci may add another level of complexity.
The second X chromosome is normally inactivated in females, however X-linked genes can escape X inactivation. With many immune genes located on the X chromosome, enhanced immunity of females and their increased risk for autoimmunity may be due to X escape genes [18] . X chromosome inactivation occurs in female human embryonic stem cells as well as human induced pluripotent stem cells that are being used for regenerative medicine experiments. Several studies have shown epigenetic instability of X chromosome inactivation over time in culture [19] [20] [21] [22] . This should be a significant consideration when selecting these cell lines for modeling any female disease. Other X chromosome-related processes that can occur, such as X skewing and mosaic loss of the X chromosome are increasingly being linked to female-predominant [23] . All these X chromosome mechanisms appear to be age-related.
Optimally, experiments should be conducted using both male and female cells in order to identify sex differences at the earliest stage of drug development. Studying cells of both sexes is simpler if primary cultures are used. Primary cell cultures are derived directly from excised animal or human tissue and grown in vitro either as an explant culture or following dissociation into a single cell suspension by enzyme or mechanical digestion. When available, cells should be obtained from an equal number and variety of male and female donors in order to permit comparisons. For example, new preclinical strategies using human stem cell cardiomyocytes are being explored to improve the detection of drug-induced cardiac arrhythmias linked to long Q-T syndrome [24] . These models should include and compare female and male human stem cells.
Single cell types can be serially propagated in culture either for a limited number of cell divisions or indefinitely to generate cell lines. Cell lines of a finite lifespan usually retain their original genetic makeup and these are best for investigating potential sex differences. On the other hand, immortalized cell lines that have been passaged many times may retain very little of their original in vivo characteristics, making it more difficult to draw conclusions about sex differences. Commercially available continuous cell lines are often derived from one sex only, which make male and female comparisons challenging to perform [12] . In these instances, new models should be developed or at the very least, the sex of the cells used in the experiment should be recorded and reported as a limitation in the research methods.
Record the age of the donor, growth conditions and passage number of the cells
It is important to know and record the age of the donor, the growth conditions and the passage number of cell lines and cultured cells. Primary cells display aging and senescent characteristics. Although immortalized cells are by their nature less susceptible to senescence, repeated passage results in the accumulation of mutations and genetic drift. These changes may lead to significant phenotypic differences in drug response.
In addition, cells go through four growth phases. The growth of cell lines is divided into a lag phase, a logarithmic growth phase, a plateau or stationary phase, and a decline phase. Each cell line will show different cell proliferation kinetics, with cellular function usually assessed during the actively proliferating growth phase. Cellular proliferation slows down during the plateau stage and at this time the cells are most susceptible to injury. Cell death predominates in the decline phase as part of the natural path of the cellular cycle. Drug response may differ depending on the abundance of cells in each of these growth phases. Cells that are actively growing and undergoing mitosis will vary in their response to drugs compared to cells in a stationary phase.
Cellular replication and senescence differs between males and females, and have been associated with sex differences in telomere length [11, 25] . The telomere is the short region of repetitive nucleotides at the end of each chromatid that protects the chromosome from deterioration or fusion with other chromosomes. However, biological differences between the sexes other than telomere attrition do exist, and include differences in genetic and physiological factors such as progressive skewing of X chromosome inactivation, mitochondrial inheritance, epigenetics, and hormonal and cellular responses to stress [26] .
Test the effects of gonadal hormones
In vitro experimentation, though critical to drug development, is inherently limited for detecting sex and age differences in humans. The only differences isolated cells can be expected to manifest are those that arise directly and solely from the chromosomal complement of each individual cell, or that have conditioned the cell in some permanent or persistent way such as through DNA methylation. When cells exist in identical and static culture conditions, sex and age differences may not be as apparent as in the human body. In the human body, a cell's response to a given compound or biologic can be modulated by hormonal or metabolic influences. For example, the action of gonadal hormones up-or down-regulates cytokine levels, cell numbers, and receptor expression for many types of immune cells, and this varies with age [27, 28] . Gonadal hormones − or sex steroids -include androgens (testosterone and its metabolite, dihydrotestosterone), progestagens (progesterone and allopregnanolone), and estrogens (estradiol, estriol, and estrone). Some investigators recommend adding a single gonadal hormone, such as estrogen or testosterone, to the cultures to examine the effect on the outcome of interest [12] . Another suggestion is to use excess or leftover cells to plate an additional few wells of the key control and experimental conditions and add in a single gonadal hormone to test whether changes occur [12] . A summary of the rec-ommendations for addressing age and sex in in vitro experiments can be found in Table 1 .
Animal experiments 2.2.1. Include both sexes
The challenges faced in translating preclinical findings to potential impact on human therapeutics is compounded when animal studies do not address or report sex and age. In a 10-year time span between 1994 and 2014 approximately 1/5 of papers did not report sex and/or age of the animals, and only 50% of the papers published from 2012 onward reported both factors [29, 30] . The impact of ignoring these two variables in animal research is significant. For example, an analysis of the heart proteome in mice at 14 and 100 weeks old demonstrated not only sex-related protein variants, but an interaction whereby more sex-related proteins were found in older mice versus younger mice [31] . These findings were reproducible in human heart tissue for 6 of the identified proteins [31] . Sex also influences the effect of anti-inflammatory compounds in large animal models of myocardial infarction [32] , with male animals demonstrating better response. Failure to consider these sex differences may partially explain the translational failure in clinical settings.
The Animals in Research: Reporting In vivo Experiments, referred to as the ARRIVE guidelines, consist of a checklist of 20 items describing the minimum information required in all scientific publications reporting research using animals [33] . The number and specific characteristics of animals used including species, strain, age, sex, weight and genetic background are included in this list. Lack of consistent design and reporting of experimental methods in preclinical work, including the description of age and sex of animals used may contribute to the fact that 80% of preclinical studies demonstrating therapeutic potential for a given disease state will not reveal a reproducible benefit when repeated in human trials [34] .
Analyse males and females separately, and as a function of age
To investigate the effects of sex, both males and females should be incorporated into all animal experiments related to drug effects, and results analysed separately for each sex [35] . Pregnant females should also be tested. Treatment response should be compared at different ages and stratified by sex. For instance, cytochrome activity has been shown to decrease in older animals for some drugs such as acetaminophen [36] and isoniazid [37] .
Several experimental approaches have been recommended to detect differences, ranging from an assessment of an overall measure of response by disaggregating small samples of males and females (e.g., peak response, area under the curve, clearance), to more complex factorial designs that are powered to detect the specific effect of each independent variable [38] . Randomized block designs can be applied when the variability within blocks is less than the variability between blocks [39] . Hormone depletion/replacement trials or sex hormone receptor knockout experiments can be used to study and identify hormonal effects [39] . A mouse 4-core genotype model exists to differentiate between gonadal and genetic sex effects [39, 40] . Several methods have been described to reliably sex embryos and neonate animals early on in development [41, 42] .
Recent meta-analyses suggest that the variability imparted by estrous cycles in female mice may be no different than the intraindividual variability observed in male mice with respect to a variety of physiologic traits [43] . The guidance to consider different phases of the estrous cycle in animal research therefore depends on the outcome of interest and whether that outcome is specifically sensitive to fluctuations in estrogen. In many cases it may still be appropriate to control for the estrous phase in preclinical studies of female animals, and this should be determined depending on the drug mechanism and response under study [44] .
Consider other experimental design factors
The ARRIVE guidelines specify documenting the housing or caging conditions of the animals [33] . Male and female mice are usually segregated in the vivarium, which can have effects on hormonal variations in testosterone and estrogen. Prendergrast et al. noted a 37% increase in variability in both males and females when mice were grouped together [43] . A variety of other environmental factors also influence differential effects by sex [45] .
Incorporating diverse animal cohorts, of different ages and sex, into drug development experiments may lead to an improvement in translation of preclinical results to clinical applications. One reason is because initial physiological descriptions of an animal model rarely encompass all salient disease features, including how closely the model captures what is observed in patients [34] . Many diseases fluctuate in incidence, severity and symptomatology according to age and sex. A homogeneous animal model may therefore be inadequate for studying how a drug affects various aspects of disease over time and in different individuals. Four tips to increase the efficiency of drug research in animals are to exclude animals that die for reasons other than the disease under study, to include males and females, to split littermates among experimental groups, and to track the genes that induce disease [34] . If genes are not inherited reliably, disease severity and drug effects may be modified. Furthermore, pharmacogenomics -the study between an individual's genetic makeup and the response to a drug at the whole genome level − may be altered [46] . Table 1 summarizes the recommendations for considering age and sex in animal experiments.
Phase 1 and 2 clinical trials in humans
In phase I trials drugs and biologics are tested in a small group of people for the first time to evaluate safety, determine a dosing range using pharmacokinetic (PK) data, and identify side effects. The goal of phase 2 trials is to administer the treatment to a larger group of people with disease to evaluate effectiveness and to assess toxicity.
Include women and older age groups
There are consistent reports that women are underrepresented in phase 1 and 2 clinical trials, at a level of 15-30% [47] . Mass balance excretion studies in humans using radiolabeled compounds to detect the mass balance of drug-related material, routes of excretion, and metabolic pathways are generally conducted in small samples of men [48] . Most bioequivalence studies are also conducted in males with the assumption that variability in PK is similar between the sexes, despite this not being the case [49] . A target of 50% female participants should be achieved in phase 1 and 2 clinical trials to detect significant sex differences. Individuals aged 75 years and older should also be included to look for PK and pharmacodynamic (PD) signals to administer reduced doses in older adults [3] .
2.3.2.
Investigate and report sex differences in drug exposure and response Table 1 lists examples of sex differences in physiologic variables that can affect drug absorption, metabolism, distribution and excretion in women, as well as PD response [50, 51] . PK differences can be attributed to fat and lean body mass, gastrointestinal transit time and pH, hepatic and renal function. Assumptions are often made that sex differences in PK are due to weight differences between women and men, however an independent sex difference may be observed [52] . Even for those sex differences that can be explained [96] endogenous and oral exogenous estrogens alter hepatic enzymes [50] ↓ first-pass metabolism [64, 97] Binding proteins: may impact drug bioavailability: ↓ binding proteins = ↑ "free/active" drug, ↑ binding proteins = ↓ "free/active" drug Albumin Possible ↓ with age; confounded by presence of illness and other factors [96] No known sex differences ↑ expression in women: organic anion transporters 2, 5 ↑ expression in men: organic anion transporter 1, urate transporter 1 [57] Would impact clearance rate of drugs excreted renally Hepatic/GI transporters ↓ Oatp1 in aged mice (greater decrease in female v male) [101] ↑ expression in women: Oatp4; equivalent in both sexes in rats [57] Would impact clearance rate of drugs excreted hepatically Multidrug resistant proteins ↓ Mrp1, Mrp3, Mrp4 with age in mice [102] ↑ expression in women: Mrp2, Mrp3 (2) ↑ expression in male rats: Mrp2 and Mrp4 [102] by differences in body weight, most drug doses are not adjusted for weight, which increases the likelihood of greater long-term exposure and potential adverse health consequences for women. The FDA guidance for PK/PD studies in humans includes recommendations for dosing adjustments based on sex, smoking and creatinine clearance [53] . There are also emerging data of sex differences in cytochrome enzymes and drug-transporter proteins ( Table 2 ). The organic anion transporting polypeptide (OATP) 1B1 is a drug-metabolizing enzyme, encoded by the SLCO1B1 gene, which is implicated in statin metabolism and shows sex-specific effects of genetic variants on statin treatment efficacy [54, 55] . Many phase 1 and 2 studies demonstrate sex differences in drug PK (Table 3 ) [56] . Differences in PK, PD, and pharmacogenomics have been extensively reviewed and highlight the need for comparing male and female phase 1 and phase 2 trial data [46, 57] .
One of the most well-recognized PD example of sex differences is the increased rate of QT prolongation in women and thus increased risk of the cardiac arrhythmia Torsades de Pointes (Table 2 ) [56] . All new molecular entities are required to test for effects on the QT interval using the Thorough QT (TQT) protocol, with standardized cutoffs for men and women. Individual dosing of drugs known to prolong QT interval has been suggested, and in some cases these drugs exert both a PK and PD effect that is more pronounced in women. For example, dofetilide not only increases the risk of QT prolongation but also exhibits 14-22% higher exposure in women compared with men, even after adjustment for weight and creatinine clearance [56] . Sex differences in Table 3 Examples of drugs that exhibit sex differences in pharmacokinetics and/or pharmacodynamics.
Drug
Treatment Target Impact of Sex Tirilizad Brain injury PK: Efficacy not shown in women which prevented drug from being approved/marketed; retrospective analysis of PK data demonstrated 149% higher clearance rate in women vs. men, suggesting under dosage contributed to lack of efficacy in women [76] . Zolpidem Insomnia PK/PD: Early PK data showed greater AUC in women vs. men; bioequivalence studies failed due to interindividual variability and were approved when women were removed from phase 2 trials, thus reducing variability. No dose adjustment was required in women until twenty years post-market when driving safety data showed greater rates of adverse events in women vs. men [77] . Propranolol Hypertension PK: Higher clearance rate in men v women, thus women have greater potential efficacy for same dose and greater potential for adverse events [50] . Quinidine Anti-arrhythmic PD: Greater QTc prolongation in women v men for same plasma concentration [56] . Dofetilide Anti-arrhythmic PK/PD: Systemic exposure in women is 14-22% higher than men after correction for body weight; consequently, women have 3-fold risk of Torsades de Pointes [56] . Ondansetron Antinausea/vomiting PK: women have higher peak concentrations and lower clearance rates, but no dose adjustment on label [56] .
PK/PD effects of several cardiovascular and diabetes drugs have been described [46, 51] . Immunogenicity is highly sex-specific and relevant to the testing of vaccines and biologics, with women mounting almost twice the antibody titer response to the influenza vaccine compared to men [27, 28, 58] . Despite this, studies on the potential sources of inter-subject variability in monoclonal antibody PK remain sparse [59] . Preliminary data suggest that the ability to bind antibodies varies with age and sex, though further research is required [59] .
Investigate and report age differences in PK and PD
Adults over the age of 75 are also underrepresented in phase 1 and 2 trials and thus age effects on PK/PD of therapeutic agents are not well known [8, 60] . Age-related declines in renal and hepatic function, and changes in body composition, are well described and often contribute to greater bioavailability of drugs in older individuals (Table 2 ) [60] [61] [62] [63] [64] . There is a trend of general pharmacodynamic sensitivity in older people, however this is not universal [65] . Frail older adults are especially prone to deterioration in physiologic parameters, such as glomerular filtration. Addition of frailty to a one-compartment linear pharmacokinetic model reduced the random variability in gentamicin clearance by 12% after adjustment for renal function and lean body weight [66] . The exclusion of older adults from phase 1 and 2 clinical trials due to concerns of multimorbidity, polypharmacy and frailty can be partially addressed by proposed mathematical models that predict the impact of aging physiological systems on drug metabolism [60] . However, inclusion of a heterogeneous group of older adults in trials is recommended to validate the mathematical models.
Age by sex interactions have been observed with some drugs, such as zolpidem, where a higher peak concentration and bioavailability of the drug was observed in older compared to younger persons, and in older women more than in older men [67] . Older women are also more susceptible to hyponatremia from treatment with vasopressin compared to older men, and younger individuals [68] . In these two instances dose adjustments and possible avoidance are recommended to offset PK and PD differences.
Individuals over 65 years of age are the most likely to receive drug prescriptions, so understanding the impact of age on PK/PD should include consideration of drug-drug interactions [69] . The US FDA and the International Conference on Harmonization propose guidance to improve the conduct of PK studies in older adults and in patients with polypharmacy [70, 71] . These guidelines provide detailed recommendations for industry regarding in vivo and clinical trial evaluation of drug metabolism and drug transporter interactions.
Sex and age-specific data collection and biomarkers
Collection of data related to age and sex that can affect drug exposures and response in phase 1 and 2 trials are listed in Table 4 . Essential information for women includes pre-menopausal and post-menopausal status, and whether exogenous oral contraceptive or hormone replacement therapy is being used. The selection of questionnaire data will vary depending on the drug, biologic and disease being studied. Table 3 also lists laboratory parameters and biomarkers that systematically differ by sex, such as glomerular filtration rate and hemoglobin. Biomarkers measure normal biological and pathological processes and also the response of the body to therapy. In addition, biomarkers provide information about the mechanism of action of a drug, its efficacy, and its safety. Significant sex-based differences are seen in multiple categories of biomarkers, including lipids, adipokines, inflammation, endothelial dysfunction, myocyte injury and stress, and kidney function [72, 73] . HIV viral load and cardiac troponin levels differ between males and females, and may or may not be correlated with progression of disease [73] .
Sex-specific criteria are recommended in clinical practice guidelines for the diagnosis and treatment of select conditions such as dyslipidemia, anemia, and waist-hip ratios for healthy body weights in men and women [74] . These sex-specific cut-offs should be considered in the inclusion criteria for trials, as well as for measurement of intermediate or surrogate endpoints. Clinical significance will vary, but the application of sex-specific biomarkers may improve insights into differential response. For instance, sex has been shown to modulate the response to erythropoietin stimulating agents in haemodialysis patients [75] . Accounting for sex-specific measurement thresholds may help explain why women are observed to be poorer responders than men to such agents in clinical trials [75] .
Disaggregate pharmacokinetic and pharmacodynamic data by age and sex
Inadequate analysis for sex and age in PK/PD assessment in phase 1 and 2 drug trials risks missing safety considerations in both sexes and can lead to drugs being withdrawn along the drug development path. Table 2 highlights two examples of drugs that either never made it to market because sex differences in early-phase trials were not identified [76] , or required a dose change based on sex differences in adverse events [77] . Zolpidem is the example from the latter category, whereby early phase 1 and 2 data showing higher area-under-the curve statistics in women compared to men did not immediately warrant sex-based dosing, but a reduction in dose for women was eventually mandated 20 years later when sex differences in simulated driving response time were noted. FDA guidance suggests studying every participant in phase 1 and 2 trials at multiple time points to account for intra-individual variability [53] . This is especially relevant for women in whom reproductive hormone concentrations may vary due to natural cycling or use of exogenous hormone therapy [73] . Recommendations for addressing age and sex in phase 1 and 2 studies are reported in Table 1 .
Phase 3 drug trials in humans
In phase 3 clinical trials, new molecular compounds and biologics are tested on several hundreds or thousands of patients to assess efficacy, effectiveness and safety. Recommendations for data collection of variables related to age and sex that can affect drug exposures and response are the same for phase 3 as for phase 1 and 2 clinical trials, and are listed in Table 1 . Additional considerations for phase 3 include a priori sample size determination and recruitment strategies according to age and sex, the use of adaptive clinical trial designs to adjust for sex and age-based dosing, and the transparent analysis and reporting of differential drug effects and harms by demographic strata.
Sample size and trial design
A common mistake is to assume that the sample size of any clinical trial automatically demands doubling to permit detection of sex or age differences. Instead, investigators are encouraged to pose clinically relevant questions a priori, with hypotheses driven substantively by preliminary data obtained from phase 1 or 2 trials, or model simulations [60] . Two frequent considerations for sample size calculations to distinguish age and sex strata relate to (1) defining the minimally clinically important difference of interest in drug efficacy or safety between groups of individuals receiving the same treatment; and (2) being able to calculate the magnitude of effect compared to the comparator for two given populations, within a pre-specified margin of error. Post-hoc analyses that are underpowered consistently fail to address these issues, especially for individuals in the oldest age ranges, making it difficult to recommend treatment decisions based on a more individualized assessment of benefit and risk.
The broad directive in the 2005 International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines states that women should achieve adequate representation in trial populations, typically reflecting the approximate extent one would predict from the prevalence by sex of the disease or condition being studied [47] . Adhering to this approach is problematic for two reasons [78] . First, because it may be difficult to reliably ascertain the exact sex distribution of a specific disease or condition, without taking age into account. The incidence of cardiovascular disease is such an example, as men tend to suffer from acute coronary syndrome earlier in life than women. The second reason is the failure to recognize that appropriate sample size calculations are meant to answer clinical questions related to benefit and risk, and not ethical considerations of equality and equity.
A 2013 U.S. Food and Drug Administration report confirmed that women are now being adequately represented in phase 3 drug trials [79] . Though well-intentioned, criticisms remain about the lack of external validity of drug trial findings due to rigid inclusion and exclusion criteria, and why such evidence often fails in the prediction of the clinical utility and harms of the drug for different patient populations in the real world setting [80] . Including women in drug trials is insufficient if the efficacy outcomes and frequency of adverse events are not disaggregated and reported by sex [81] .
Few trials set age limits for individuals aged 75 years and older, however there is continued widespread use of exclusion criteria based on comorbidities and concomitant medication use [8] . Depending on the market share of the intended use of a given drug, investigators may want to consider weighting the 75-year-plus age category in their recruitment and sample size calculations, as loss to follow up and censure may be higher in the oldest old. Missing information caused by death can lead to bias in the relative estimates of benefit and harm for older individuals [82] . Classifying and analyzing trial results according to ten-year age brackets from 65 to 74,75 to 84, 85 to 94 and 95 years and older will help inform treatment [83] .
The adaptive clinical trial design is a new method for determining dose selection by age and sex in phase 3 trials [84] . Sample size re-estimation protocols and seamless phase 2-3 trial designs permit detailed dose selection for subgroups of interest to occur midway through the trial or between phase 2 and phase 3 trials respectively, while conserving sample size efficiency. Trials that require rapid recruitment or lengthy patient follow-up (e.g., assessment of the primary endpoint over a period of a few years after treatment) may not be suitable for adaptive designs, since enrollment may be almost complete by the time the follow-up requirement is met to allow decision-making on dose adjustment.
Recruitment
Novel methods for improving recruitment and retention of women in clinical trials are being discussed [85] . Strategies include working with more female physicians, promoting culturally sensitive communications, raising awareness of why participation is important, and involving communities. Similar considerations apply to the recruitment and retention of older individuals in clinical trials [86] . Older adults appear to be least interested in participating in pharmacological intervention trials compared to other treatment modalities, despite pharmacological interventions being rated as more likely to result in new treatments for Alzheimer's disease [87] .
Two additional populations to be targeted for inclusion and retention in clinical trials are pregnant women and individuals who are unable to provide consent, such as older adults with dementia. Participation of pregnant and postpartum women should be encouraged in drug trials where evidence from animal data suggests that the drug is not harmful to the fetus or to the infant through means of lactation [88] . The revised Council for International Organizations of Medical Sciences Ethical Guidelines for Health-Related Research Involving Humans call for increased attention to safety in accruing sufficient numbers of individuals to enable robust conclusions about treatment efficacy in pregnant women and populations with dementia [89] .
Analysis and reporting of drug effectiveness and safety by age and sex
A review of randomized controlled trials published in The Lancet and The New England Journal of Medicine between April 1, 2016, and July 16, 2016 identified 60 trials that included men and women. Across the 54 trials that reported the breakdown by sex of the study sample, 41% of participants were female. No trial had a prespecified analysis of differences by sex and only 29 (48%) of the trials published reported sex-related analyses in the results section. In a review of the clinical trials done with rofecoxib after the drug was withdrawn from the market, it was noted that 80% of the trials did not describe efficacy results by sex, only one study reported side effects by sex and only 8% considered the influence of sex hormones [90] . Had results been reported by sex, a significant amount of morbidity and mortality from Vioxx may have been avoided.
The Sex and Gender Equity in Research guidelines promotes disaggregation by sex as a minimal quality standard in the reporting of research results [35] . Recommendations for how to consider reporting sex in clinical trials have been published [81] . Stratification by age is also required. Tables and figures showing the magnitude of effect of a drug, or the occurrence of side effects should represent the observed outcomes for each age and sex group. The FDA's Drug Trial Snapshots initiative reports on the diversity of participants in clinical trials and the extent to which safety and effectiveness data is based on demographic factors such as sex, age, and race [91] . In 2016, the FDA approved 22 novel drugs either as new molecular entities or as new therapeutic biologics. Women represented 48% of clinical trial participants, while adults over age 65 comprised only 21% of trial populations. Sex and age-specific outcomes are not yet featured on the Drug Trial Snapshots webpage, making it difficult to make decisions about individualizing therapy based on demographics. Table 1 summarizes recommendations for addressing age and sex in phase 2 trials.
Post-marketing studies
Many countries such as Canada, the United States, the United Kingdom and the European Union adhere to post marketing pharmacovigilance requirements, with a focus on the safety of therapeutic products. Spontaneous adverse event reporting, as well health insurance or drug claims datasets can be used to mine information on the post-approval performance of drugs and biologics in the general population. As with phase 1,2 and 3 studies in humans, all post-marketing analyses should disaggregate results by age and sex, and analyse sex by age interactions. Sex and agespecific data submitted to regulatory agencies should be accessible to researchers in the spirit of data sharing and for purposes of reanalysis or meta-analysis. Labeling changes and warnings should be issued if safety concerns emerge, as was the case for zolpidem [67] . Reverse translating observations into new basic science research on sex and age-specific mechanisms may lead to new therapeutics and enhanced biologic products (Fig. 1) . A new paradigm is needed that encourages a perpetual, reflective and continuous cycle of translational and post-translational research that will drive the development of new sex-specific drug targets, and safer age-and sex-based drug dosing.
Challenges associated with implementing recommendations on age and sex
Many commercial cell lines do not identify the sex of the cells or are available in one sex only [11, 92] . New animal models of disease may need to be developed in order to compare sex or age differences [93] . The duration of animal experiments will be longer if changes across the lifespan are studied. Animal models of aging exist, but may not be relevant for drug testing across all disease states [94] . Sample size may need to be expanded. All these limitations raise concerns that integrating sex and age into research experiments will increase costs. Furthermore, it may be more labour-intensive to accrue sufficient numbers of female participants and individuals older than 75 into trials. Adding new data collection parameters and laboratory tests for estrogen or testosterone could increase participant burden.
A counterargument to these concerns is the lack of return on investment and wasted resources that result from not studying both sexes and the impact of age on drug development. In animal research, a minimal investment of $US330,000 is required to determine what dose of a drug has reasonable potential to be tested in humans [34] . The average cost of human drug trials is even more prohibitive, with phase 1 studies ranging from US$1.4 million (pain and anesthesia) to US$6.6 million (immunomodulation). Phase 2 studies cost from US$7.0 million (cardiovascular) to US$19.6 million (hematology), and phase 3 studies require an investment of US$11.5 million (dermatology) to US$52.9 (pain and anesthesia) on average [95] . Failure to appropriately assess drug benefits and harms in females and across the lifespan is not only ethically questionable but overall contributes to economic waste. Cost efficiency is further reduced if dose adjustments are required after marketing approval.
Discussion and conclusion
A historic protection of women and the elderly as "vulnerable populations" in whom the risk-benefit ratio of participating in early phase clinical trials was deemed unfavourable has left significant gaps in the understanding of drug effects in these majority populations. The inclusion of women in clinical trials has increased overall. There remains a persistent underrepresentation of women and older adults in early phase trials and in certain therapeutic areas that significantly impact women. Sex and age differences in PK/PD highlight the need for stratified demographic analyses of phase 1 and 2 data by sex and age to increase the likelihood of efficacy and reduction of adverse drug reactions. In vitro and preclinical animal studies should also take a sex-and age-based approach to the early phase discovery of drug targets. Studies should include both sexes in cell lines and animal models, reporting details such as tissue origin, sex and age, and following the ARRIVE guidelines to ensure adequate control for variability associated with factors such as segregated housing by sex. Alignment with these guidelines will improve reproducibility and translation of preclinical work of early phase drug discovery that may eventually lead to clinical therapeutics.
The recommendations in this paper summarize guidance for drug development and testing across the spectrum of age and sex in human adults. Analyzing the outcomes of drug trials that include diverse populations with equal numbers of women and men, and adequate representation of individuals aged over 75 years is required. Designing trials with pre-specified outcomes and collection of variables that allow investigators to address sex and age differences in PK, PD, efficacy, and safety will undoubtedly improve our ability to tailor pharmacologic treatments to the appropriate patients for the best outcomes with the lowest possible risk.
